A facility headquartered at AIBN has received $4.59 million from the Queensland Government to continue its innovative research and industry projects such as needle-free vaccine delivery.
Researchers from the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology (AIBN) have discovered a unique nano-scaled DNA signature that appears to be common to all cancers.
Research led by Professor Gordon Xu of the Australian Institute for Bioengineering and Nanotechnology (AIBN) has shown that clay nanoparticles can significantly boost immune responses as vaccine adjuvants.